Оценка качества жизни пациентов после радикального лечения рака предстательной железы

В статье представлен обзор современных данных о качестве жизни онкологических пациентов после проведенного радикального лечения рака предстательной железы, а также о функциональных результатах этого лечения. Основная цель работы ‒ оценка функциональных результатов у пациентов после радикальной простатэктомии, сочетанной лучевой терапии и брахитерапии высокой мощностью дозы в монорежиме спустя 8–12 мес. после проведенного лечения. В исследование было включено 148 пациентов, проходивших лечение с 2017 по 2018 г. Функциональные результаты и качество жизни пациентов оценивали посредством специализированного опросника. Полученные после проведения лучевой терапии результаты свидетельствуют о лучших функциональных результатах и более высоком уровне качества жизни пациентов, чем после выполнения радикальной простатэктомии.

1. The development of the WHO quality of life assessment instruments (the WHOQOL) / WHOQOL Group // Quality of life assessment: international perspectives : proceedings of the joint-meeting organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993 / ed. : J. Orley, W. Kuyken. – Berlin, 1994. – P. 41−57.

2. Базисные принципы и методология доказательной медицины / В. И. Петров // Вестн. Волгоград. гос. мед. ун-та. – 2011. – № 2. – С. 3–9.

3. Hays, R. D. Measurement and modeling of health-related quality of life / R. D. Hays, B. B. Reeve // International Encyclopedia of public health / ed. : K. Heggenhougen, S. R. Quah. Amsterdam ; Boston, 2008. – P. 241–252.

4. Torrance, G. W. Utility approach to measuring health-related quality of life / G. W. Torrance // J. Chron. Dis. – 1987. – Vol. 40, N 6. – P. 593–600. https://doi.org/10.1016/0021-9681(87)90019-1

5. Ebrahim, S. Clinical and public health perspectives and applications of health-related quality of life measurement / S. Ebrahim // Soc. Sci. Med. – 1995. – Vol. 41, N 10. – P. 1383–1394. https://doi.org/10.1016/0277-9536(95)00116-O

6. The role and cost-effectiveness analysis in health and medicine / L. B. Russel [et al.] // JAMA. – 1996. – Vol. 276, N 14. – P. 1172–1177. https://doi.org/10.1001/jama.1996.03540140060028

7. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines / American Society of Clinical Oncology // J. Clin. Oncol. – 1996. – Vol. 14, N 2. – P. 671–679. https://doi.org/10.1200/JCO.1996.14.2.671

8. Health-related quality of life assessment and reported outcomes in leukaemia randomized controlled trials: a systematic review to evaluate the added value in supporting clinical decision-making / F. Efficace [et al.] // Eur. J. Cancer. – 2008. – Vol. 44, N 11. – P. 1497–1506. https://doi.org/10.1016/j.ejca.2008.03.017

9. Cancer incidence and mortality projections in the UK until 2035 / C. R. Smittenaar [et al.] // Br. J. Cancer. – 2016. – Vol. 115, N 9. – P. 1147–1155. https://doi.org/10.1038/bjc.2016.304

10. High levels of untreated distress and fatigue in cancer patients / L. E. Carlson [et al.] // Br. J. Cancer. – 2004. – Vol. 90, N 12. – P. 2297–2304. https://doi.org/10.1038/sj.bjc.6601887

11. Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study / T. A. Horsboel [et al.] // Psycho-Oncology. – 2015. – Vol. 24, N 4. – P. 408–415. https://doi.org/10.1002/pon.3658

12. Toward a national initiative in cancer rehabilitation: recommendations from subject matter expert group / N. L. Stout [et al.] // Arch. Phys. Med. Rehabil. – 2016. – Vol. 97, N 11. – P. 2006–2015. https://doi.org/10.1016/j.apmr.2016.05.002

13. Attitudes of urologists towards HRQOL and its clinical use / A. Schmick [et al.] // BMC Urol. – 2017. – Vol. 17. – Art. 46. https://doi.org/10.1186/s12894-017-0235-1

14. Blazeby, J. M. The prognostic value of quality of life scores during treatment for esophageal cancer / J. M. Blazeby, S. T. Brookes, D. Aldersona // Gut. – 2001. – Vol. 49, N 2. – P. 227–230. http://dx.doi.org/10.1136/gut.49.2.227

15. EORTC clinical groups: baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials / C. Quinten [et al.] // Lancet. Oncol. – 2009. – Vol. 10, N 9. – P. 865–871. https://doi.org/10.1016/S1470-2045(09)70200-1

16. The prognostic significance of patient-reported outcomes in cancer clinical trials / C. C. Gotay [et al.] // J. Clin. Oncol. – 2008. – Vol. 26, N 8. – P. 1355–1363. https://doi.org/10.1200/JCO.2007.13.3439

17. Jylhä, M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model / M. Jylhä // Soc. Sci. Med. – 2009. – Vol. 69, N 3. – P. 307–316. https://doi.org/10.1016/j.socscimed.2009.05.013

18. Guideline for good clinical practice. ICN harmonized tripartite guideline. – Geneva : WHO, 1996. – 56 p.

19. Quality-of-life measurement in advanced cancer: assessing the individual / D. Waldron [et al.] // J. Clin. Oncol. – 1999. – Vol. 17, N 11. – P. 3603–3611. https://doi.org/10.1200/JCO.1999.17.11.3603

20. The use, feasibility and psychometric properties of an individualized quality-of-life instrument: a systematic review of the SEIQoL-DW / L. Wettergren [et al.] // Qual. Life. Res. – 2009. – Vol. 18, N 6. – P. 737–746. https://doi.org/10.1007/s11136-009-9490-2

21. Anderson, R. T. Critical review of the international assessments of health-related quality of life / R. T. Anderson, N. K. Aaronson, D. Wilkin // Qual. Life. Res. – 1993. – Vol. 2, N 6. – P. 369–395. https://doi.org/10.1007/BF00422215

22. Australian WHOQoL instruments: user’s manual and interpretation guide / B. Murphy [et al.]. – Melbourne, Australian WHOQoL Field Study Centre, 2000.

23. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines / R. Etzioni [et al.] // Cancer. – 2012. – Vol. 118, N 23. – P. 5955–5963. https://doi.org/10.1002/cncr.27594

24. Prostate cancer mortality in areas with high and low prostate cancer incidence / P. Stattin [et al.] // J. Nat. Cancer Inst. – 2014. – Vol. 106, N 3. – P. dju007. https://doi.org/10.1093/jnci/dju007

25. Скрининг рака предстательной железы в Республике Беларусь / С. А. Красный [и др.]. – Минск : Принтхаус, 2015. – 158 с.

26. Статистика онкологических заболеваний в Республике Беларусь 2007–2016: Белорусский канцер-регистр / А. Е. Океанов [и др.] ; под ред. О. Г. Суконко. – Минск : РНПЦ ОМР им. Н. Н. Александрова, 2017. – 286 c.

27. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis / J. Hayes [et al.] // Ann. Int. Med. – 2013. – Vol. 158, N 12. – P. 853–860. https://doi.org/10.7326/0003-4819-158-12-201306180-00002

28. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer / A. Kalbasi [et al.] // JAMA Oncol. – 2015. – Vol. 1, N 7. – P. 897–906. https://doi.org/10.1001/jamaoncol.2015.2316

29. High-dose-rate monotherapy for localized prostate cancer: 10-year results / H. Hauswald [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2016. – Vol. 94, N 4. – P. 667–674. https://doi.org/10.1016/j.ijrobp.2015.07.2290

30. Prospective quality of life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy / C. Jeldres [et al.] // Cancer. – 2015. – Vol. 121, N 14. – P. 2465–2473. https://doi.org/10.1002/cncr.29370

31. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study / J. Fridriksson [et al.] // Scand. J. Urol. – 2016. – Vol. 50, N 5. – P. 338–345. https://doi.org/10.1080/21681805.2016.1194460

32. Population-based study of long-term functional outcomes after prostate cancer treatment / S. Carlsson [et al.] // BJU Int. – 2016. – Vol. 117, N 6B. – P. E36–E45. https://doi.org/10.1111/bju.13179

33. Long-term quality-of-life outcomes after radical prostatectomy of watchful waiting: the Scandinavian Prostate Cancer Group-4 randomized trial / E. Johansson [et al.] // Lancet Oncol. – 2011. – Vol. 12, N 9. – P. 891–899. https://doi.org/10.1016/S1470-2045(11)70162-0

34. Quality of life and satisfaction with outcome among prostate-cancer survivors / M. Sanda [et al.] // N. Engl. J. Med. – 2008. – Vol. 358. – P. 1250–1261. https://doi.org/10.1056/NEJMoa074311

35. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer / J. Donnovan [et al.] // N. Engl. J. Med. – 2016. – Vol. 375, N 15. – P. 1425–1437. https://doi.org/10.1056/NEJMoa1606221

36. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques / M. Morgan [et al.] // J. Contemp. Brachytherapy. – 2018. – Vol. 10, N 6. – P. 495–502. https://doi.org/10.5114/jcb.2018.81024

37. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire / M. Leeuwen [et al.] // Health Qual. Life Outcomes. – 2018. – Vol. 16, N 1. – P. 114. https://doi.org/10.1186/s12955-018-0920-0

38. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology / N. Aaronson [et al.] // J. Nat. Cancer Inst. – 1993. – Vol. 85, N 5. – P. 365–376. https://doi.org/10.1093/jnci/85.5.365

39. Pearce, N. J. Measuring quality of life in cancer survivors: a methodological review of existing scales / N. J. Pearce, R. Sanson-Fisher, H. Campbell // Psycho-Oncology. – 2007. – Vol. 17, N 7. – P. 629–640. https://doi.org/10.1002/pon.1281

40. Baker, F. Development of the Satisfaction with Life Domains Scale for Cancer / F. Baker, B. Curbow, J. R. Wingard // J. Psychosoc. Oncol. – 2008. – Vol. 10, N 3. – P. 75–90. https://doi.org/10.1300/j077v10n03_05

41. Avis, N. E. Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for long-term cancer survivors in a sample of breast cancer survivors / N. E. Avis, E. Ip, K. L. Foley // Health Qual. Life Outcomes. – 2006. – Vol. 4. – Art. 92. https://doi.org/10.1186/1477-7525-4-92

42. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure / M. Litwim [et al.] // Med. Care. – 1998. – Vol. 36, N 7. – P. 1002–1012. https://doi.org/10.1097/00005650-199807000-00007

43. Measuring and predicting prostate cancer related quality of life changes using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) / J. Chipman [et al.] // J. Urol. – 2014. – Vol. 191, N 3. – P. 638–645. https://doi.org/10.1016/j.juro.2013.09.040

44. Апробация «Универсального опросника качества жизни больных раком предстательной железы» / С. А. Ракул [и др.] // Онкоурология. – 2009. – Т. 5, № 2. – С. 64–73.

45. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomized controlled study / G. D. Coughlin [et al.] // Lancet Oncol. – 2018. – Vol. 19, N 8. – P. 1051–1060. https://doi.org/10.1016/S1470-2045(18)30357-7

46. Брахитерапия высокой мощностью дозы при раке предстательной железы / С. О. Голдыцкий [и др.] // Здравоохранение. – 2019. – № 3. – С. 40–45.